 Biomarker evaluation: All assays for primary and secondary endpoints will be analyzed after concluding with patient recruitment. Nuclear Ki-67 staining will be evaluated according to Goldhirsch et al., 2013, and other biomarkers will be evaluated at the end of the study comparing biopsy and surgery scores of all patients recruited. Cytoplasmic, nuclear and membrane stainings will also be considered for biomarkers other than hormone receptors and Ki-67. Tumors with Ki-67 scoring differences greater than 10 between the two pathologists will be reevaluated until complete agreement is obtained. For differences less than 10, the average score will be considered. If a positive response is seen 30 change in biomarker expression between biopsy and surgery, the investigators will start with the molecular analysis of the samples using available genomic platforms. 